Sign inCreate account

Report workspace tools

NCT04658914COMPLETEDanonymous

Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa

Sponsor

Source record

Centre for Infectious Disease Research in Zambia

Phase

Source record

Phase 2

Modality

AI-normalized

cell therapy

Target

AI-normalized

Rotavirus

Indication / condition

AI-normalized

Diarrhea

Intervention

Source record

Rotarix, Trivalent P2-VP8

Source & freshness

Source record

NCT ID

NCT04658914

Original source

ClinicalTrials.gov

Source last updated

May 15, 2025

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04658914

Title

Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa

Sponsor

Centre for Infectious Disease Research in Zambia

Status

COMPLETED

Phase

Phase 2

Condition raw

Diarrhea

Condition normalized

Diarrhea

Modality raw

Diarrhea

Modality normalized

cell therapy

Target raw

Rotavirus

Target normalized

Rotavirus

Interventions

Rotarix, Trivalent P2-VP8

Public preview

Source record

This clinical trial evaluates a novel trivalent VP8 subunit rotavirus vaccine in combination with the existing Rotarix vaccine to enhance immune response in infants in Zambia. The study aims to address the ongoing morbidity and mortality associated with rotavirus infections despite existing vaccination efforts.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04658914

Status

COMPLETED

Phase

Phase 2

Sponsor

Centre for Infectious Disease Research in Zambia

Executive brief

Investment-Ready Snapshot

This clinical trial evaluates a novel trivalent VP8 subunit rotavirus vaccine in combination with the existing Rotarix vaccine to enhance immune response in infants in Zambia. The study aims to address the ongoing morbidity and mortality associated with rotavirus infections despite existing vaccination efforts.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 15, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04658914

Indication

Diarrhea

Modality

cell therapy

Target

Rotavirus

Intervention

Rotarix, Trivalent P2-VP8

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.